[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339066-105":59,"doc-detail-339066-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","locoregional-therapies-for-hepatocellular-carcinoma-the-current-status-and-future-perspectives-review-article","Locoregional therapies for hepatocellular carcinoma - The current status and future perspectives - Review article","","Hepatocellular carcinoma (HCC) is among the most common cancers and a major cause of cancer-related mortality. Locoregional therapies (LRTs) are crucial across multiple disease stages and selection depends on technical factors, patient clinical status, and tumor characteristics. Evidence supports combining LRTs with molecular targeted agents, while emerging studies indicate that adding immune checkpoint inhibitors may yield substantial additional benefit. This review summarizes the current LRT landscape and discusses expected outcomes from immunotherapy combinations.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/locoregional-therapies-for-hepatocellular-carcinoma-the-current-status-and-future-perspectives-review-article/339066/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/locoregional-therapies-for-hepatocellular-carcinoma-the-current-status-and-future-perspectives-review-article/339066.png","ImageObject",300,407,{"name":92,"@type":93},"Lucas Martin","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-22","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What determines the choice of locoregional therapies (LRTs) for hepatocellular carcinoma?","Question",{"text":112,"@type":113},"Selection depends on technical aspects, patient clinical status, and tumor characteristics. Different stages and regional practice patterns also influence which LRTs are used.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical staging systems guide LRT indications for HCC?",{"text":117,"@type":113},"The Barcelona Clinic Liver Cancer (BCLC) model is described as the predominant approach, and early- to intermediate-stage HCC is primarily indicated for LRTs. The review also references alternative guidance such as China Liver Cancer (CNLC) and Japan Society of Hepatology (JSH) recommendations, which differ in LRT indications.",{"name":119,"@type":110,"acceptedAnswer":120},"How are LRTs being combined with systemic therapies?",{"text":121,"@type":113},"Past studies highlight efficacy when LRTs are combined with molecular targeted agents. Recent evidence proposes that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents may provide additional therapeutic benefits, supported by basic and clinical data.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339066,1790914072,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},8796095360427,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","DOI: 10. 1002/ueg2.12554  \nREVIEW ARTICLE  \nLocoregional therapies for hepatocellular carcinoma: The current status and future perspectives  \nJian‐Jian Chen1  | Zhi‐Cheng Jin1  | Bin‐Yan Zhong2  | Wenzhe Fan3 | Wei‐Hua Zhang 1 | Biao Luo1 | Yu‐Qing Wang1 | Gao‐Jun Teng1  | Hai‐Dong Zhu1   \n1Department of Radiology, Center of Interventional Radiology & Vascular Surgery, Zhongda Hospital, Medical School, Southeast University, Nanjing, China 2Department of Interventional Radiology, The First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China  \n3Department of Interventional Oncology, The First Affiliated Hospital of Sun Yat‐sen University, Guangzhou, China  \nCorrespondence  \nHai‐Dong Zhu, Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing 210009, China.  \nEmail: [zhuhaidong9509@163.com](zhuhaidong9509@163.com)  \nFunding information  \nNational Natural Science Foundation of China, Grant/Award Numbers: 81827805, 82130060, 61821002; National Key Research and Development Program of China, Grant/ Award Numbers: 2018YFA0704100, 2018YFA0704104; Jiangsu Provincial Medical Innovation Center, Grant/Award Number: CXZX202219; Collaborative Innovation Center of Radiation Medicine of Jiangsu Higher Education Institutions, and Nanjing Life Health Science and Technology Project, Grant/ Award Number: 202205045  \nAbstract  \nHepatocellular carcinoma (HCC) is one of the most common cancers and a leading cause of cancer‐related mortality. Locoregional therapies (LRTs) play a crucial role in HCC management and are selectively adopted in real‐world practice across various stages. Choosing the best form of LRTs depends on technical aspects, patient clinical status and tumour characteristics. Previous studies have consistently highlighted the efficacy of combining LRTs with molecular targeted agents in HCC treatment. Recent studies propose that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents could provide substantial therapeutic benefits, a notion underpinned by both basic and clinical evidence. This review summarised the current landscape of LRTs in HCC and discussed the anticipated outcomes of combinations with immunotherapy regimens.  \nKEYWORDS  \ncombined modality therapy, hepatocellular carcinoma, immune checkpoint inhibitors, locoregional therapy, molecular targeted therapy  \nINTRODUCTION  \nHepatocellular carcinoma (HCC) is one of the most common cancersand a leading cause of cancer‐related death worldwide.1 The Barcelona Clinic Liver Cancer (BCLC) staging system is the predominant model for HCC management.2 According to the BCLC guidelines, locoregional therapies (LRTs) are primarily indicated for early‐ and intermediate‐stage HCC. Reflecting regional clinical practices, alternative guidelines and consensus statements have been developed,  \nsuch as the China Liver Cancer (CNLC) staging system and the Japan Society of Hepatology (JSH) consensus statements.3–5 These guidelines exhibit notable differences in the indications for LRTs.4–7 The therapeutic objectives of LRTs, as outlined in various guidelines, emphasise curative intent in the early stage, disease control in the intermediate stage and palliative care in the advanced stage.  \nLRTs, pivotal in HCC management, encompass tumour‐targeted procedures under imaging guidance, generally categorised into the percutaneous approach and the intra‐arterial approach.8,9 The  \n\n| Jian‐Jian Chen, Zhi‐Cheng Jin, Bin‐Yan Zhong and Wenzhe Fan contributed equally. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.\u003Cbr>© 2024 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC on behalf of ","cbCaiheYnqeAcjE9","https://ap.wps.com/l/cbCaiheYnqeAcjE9","pdf",399972,14,"English","# Abstract\n# Introduction\n# Overview of Loco regional Therapies\n## Local ablation\n## Intra-arterial therapies","[{\"question\":\"What determines the choice of locoregional therapies (LRTs) for hepatocellular carcinoma?\",\"answer\":\"Selection depends on technical aspects, patient clinical status, and tumor characteristics. Different stages and regional practice patterns also influence which LRTs are used.\"},{\"question\":\"Which clinical staging systems guide LRT indications for HCC?\",\"answer\":\"The Barcelona Clinic Liver Cancer (BCLC) model is described as the predominant approach, and early- to intermediate-stage HCC is primarily indicated for LRTs. The review also references alternative guidance such as China Liver Cancer (CNLC) and Japan Society of Hepatology (JSH) recommendations, which differ in LRT indications.\"},{\"question\":\"How are LRTs being combined with systemic therapies?\",\"answer\":\"Past studies highlight efficacy when LRTs are combined with molecular targeted agents. Recent evidence proposes that integrating LRTs with immune checkpoint inhibitors and molecular targeted agents may provide additional therapeutic benefits, supported by basic and clinical data.\"}]","Locoregional therapies for hepatocellular carcinoma - The current status and future perspectives - Review article | PDF",1790027678,35]